Sucampo and Takeda Introduce Amitiza 8mcg Capsules in US

Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America have announced that Amitiza 8mcg capsules are now available by prescription in pharmacies across the US for the treatment of irritable bowel syndrome with constipation in women 18 years and older.

Amitiza has a mechanism of action that works locally in the intestine to increase fluid secretion, resulting in increased passage of stool and alleviating symptoms associated with chronic idiopathic constipation.

Amitiza was developed by Sucampo Pharmaceuticals and is co-marketed in the US by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.

Ryuji Ueno, founder, chairman and CEO of Sucampo, said: “I am very pleased with the quick commercial launch of Amitiza 8mcg for this particular indication as it could provide a treatment option to many adult women suffering from irritable bowel syndrome with constipation.”